Literature DB >> 25835558

Polyanionic carbosilane dendrimer-conjugated antiviral drugs as efficient microbicides: Recent trends and developments in HIV treatment/therapy.

Daniel Sepúlveda-Crespo1, Rafael Gómez2, Francisco Javier De La Mata2, José Luis Jiménez3, M Ángeles Muñoz-Fernández4.   

Abstract

Polyanionic carbosilane dendrimers (PCDs) are potential candidates for the development of new microbicides for the prevention of HIV transmission. Tenofovir (TFV), which has dual antiviral activity (anti-HIV/HSV-2), and maraviroc (MRV) are the most studied antiretrovirals as microbicides. Here, we introduce developments in the design of innovative dendrimer-based microbicides. We also review and discuss the combination of various PCDs with TFV and/or MRV for their anti-HIV-1 activity and synergistic combinatory potential. Well-defined combinations blocking HIV-1 infection in early steps of HIV-1 replication provide greater efficacy than monotherapy, as reflected by the decrease in concentration and increase in HIV-1 inhibition. These combinations are characterized by lower doses, which minimize toxic side-effects and the emergence of multi-drug resistant mutants. The above facts suggest that the combination of first- and second-generation PCDs with TFV and/or MRV represents a promising candidate microbicide for preventing HIV-1 sexual transmission and simultaneously suppressing HSV-2. FROM THE CLINICAL EDITOR: HIV infection remains a significant and unresolved problem for humankind, despite the development of combination antiretroviral therapy. It has been found that polyanionic carbosilane dendrimers have efficacy in preventing HIV transmission. In this comprehensive review article, the authors discuss the current status and latest development of the use of dendrimers in combination with other antiretroviral drugs as microbicides, which should stimulate others into further research in the fight against HIV.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  HIV-1/HSV-2; Maraviroc; Microbicide; Polyanionic carbosilane dendrimers; Tenofovir

Mesh:

Substances:

Year:  2015        PMID: 25835558     DOI: 10.1016/j.nano.2015.03.008

Source DB:  PubMed          Journal:  Nanomedicine        ISSN: 1549-9634            Impact factor:   5.307


  14 in total

Review 1.  The potential of HIV-1 nanotherapeutics: from in vitro studies to clinical trials.

Authors:  Upal Roy; Jesse Rodríguez; Paul Barber; José das Neves; Bruno Sarmento; Madhavan Nair
Journal:  Nanomedicine (Lond)       Date:  2015-09-24       Impact factor: 5.307

Review 2.  Nanomedicine based approaches for combating viral infections.

Authors:  Saurabh Shah; Mahavir Bhupal Chougule; Arun K Kotha; Rama Kashikar; Chandraiah Godugu; Rajeev Singh Raghuvanshi; Shashi Bala Singh; Saurabh Srivastava
Journal:  J Control Release       Date:  2021-08-08       Impact factor: 11.467

Review 3.  Baseline and time-updated factors in preclinical development of anionic dendrimers as successful anti-HIV-1 vaginal microbicides.

Authors:  Ignacio Rodríguez-Izquierdo; Daniel Sepúlveda-Crespo; Jose María Lasso; Salvador Resino; Ma Ángeles Muñoz-Fernández
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2022-01-12

Review 4.  Function Oriented Molecular Design: Dendrimers as Novel Antimicrobials.

Authors:  Sandra García-Gallego; Gianluigi Franci; Annarita Falanga; Rafael Gómez; Veronica Folliero; Stefania Galdiero; Francisco Javier de la Mata; Massimiliano Galdiero
Journal:  Molecules       Date:  2017-09-21       Impact factor: 4.411

5.  Poly(N-vinylcaprolactam) Nanogels with Antiviral Behavior against HIV-1 Infection.

Authors:  Micaela A Macchione; Carlos Guerrero-Beltrán; Anabella P Rosso; Esteban M Euti; Marisa Martinelli; Miriam C Strumia; Maria Ángeles Muñoz-Fernández
Journal:  Sci Rep       Date:  2019-04-05       Impact factor: 4.379

6.  Macromolecular Antiviral Agents against Zika, Ebola, SARS, and Other Pathogenic Viruses.

Authors:  Franziska Schandock; Camilla Frich Riber; Annika Röcker; Janis A Müller; Mirja Harms; Paulina Gajda; Kaja Zuwala; Anna H F Andersen; Kaja Borup Løvschall; Martin Tolstrup; Florian Kreppel; Jan Münch; Alexander N Zelikin
Journal:  Adv Healthc Mater       Date:  2017-09-25       Impact factor: 9.933

Review 7.  Applications and Limitations of Dendrimers in Biomedicine.

Authors:  Adriana Aurelia Chis; Carmen Dobrea; Claudiu Morgovan; Anca Maria Arseniu; Luca Liviu Rus; Anca Butuca; Anca Maria Juncan; Maria Totan; Andreea Loredana Vonica-Tincu; Gabriela Cormos; Andrei Catalin Muntean; Maria Lucia Muresan; Felicia Gabriela Gligor; Adina Frum
Journal:  Molecules       Date:  2020-09-01       Impact factor: 4.411

Review 8.  Peptides and Dendrimers: How to Combat Viral and Bacterial Infections.

Authors:  Annarita Falanga; Valentina Del Genio; Stefania Galdiero
Journal:  Pharmaceutics       Date:  2021-01-14       Impact factor: 6.321

9.  Efficacy of HIV antiviral polyanionic carbosilane dendrimer G2-S16 in the presence of semen.

Authors:  Rafael Ceña-Diez; Pilar García-Broncano; Francisco Javier de la Mata; Rafael Gómez; M Ángeles Muñoz-Fernández
Journal:  Int J Nanomedicine       Date:  2016-05-30

Review 10.  Dendrimer-Based Drug Delivery Systems for Brain Targeting.

Authors:  Yuefei Zhu; Chunying Liu; Zhiqing Pang
Journal:  Biomolecules       Date:  2019-11-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.